TURKU, FINLAND / ACCESS Newswire / March 21, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN)(AIM: FARN) (First North: FARON), a clinical-stage biopharmaceutical company pursuing a CLEVER approach ...

Companies of above-average quality don’t trade cheaply too often. When they do, it’s usually because investors are concerned ...

I maintain a Neutral view on CSL Limited due to the mixed prospects for its flu vaccine (Seqirus) and plasma therapy (Behring ...

TURKU, FI / ACCESS Newswire / March 20, 2025 /Faron Pharmaceuticals (HEL:FARON)(AIM:FARN) Shareholders' Nomination Board updates its recommendation on the number of Board members to be elected and the ...

CSL Ltd (ASX: CSL) shares have been sold off recently and are down near multi-year lows. Is now the time to buy?

Its long-term returns have been outstanding. Yet eroding fundamentals and today’s prohibitive valuation imply tomorrow’s ...

Analysts think these shares could be destined to deliver good returns for investors. The post 3 excellent Australian stocks ...

The ASX 200 biotech stock has lost 9% of its value since the start of the new year. The post Why is the CSL share price ...

Atlas Funds’ Phil Cornet says the weakness in the ASX 200 heavyweight makes no sense and Ampol is ripe for a rally.

On the heels of a late-stage clinical trial failure, Vifor Pharma has moved to bolster its pipeline by acquiring Spain's Sanifit and fellow Swiss biotech Inositec for a combined value of €225 ...

Looking for an oversold S&P/ASX 200 Index (ASX: XJO) share that’s relatively immune to Donald Trump’s tariffs? You’ll want to ...

CSL Vifor has said it is prepared to carry out a “comprehensive and multi-channel communication campaign” to address allegations by the EU that it disparaged one of its competitor’s products.